Introduction
============

Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are both common in the elderly, and often coexist.[@b1-copd-10-1219] Diagnosing COPD in HF is challenging because clinical features overlap, and dyspnea and fatigue are common symptoms.[@b1-copd-10-1219],[@b2-copd-10-1219] Both share smoking as an important risk factor, and they have a chronic progressive disease trajectory with systemic effects, and require complex treatment regimens.[@b3-copd-10-1219]--[@b5-copd-10-1219] The prognosis of patients with both disorders is worse than those with only one of the diseases.[@b6-copd-10-1219],[@b7-copd-10-1219] Importantly, bronchodilators may improve symptoms of COPD, but possibly cause cardiac side effects.[@b8-copd-10-1219],[@b9-copd-10-1219] Under-diagnosis of one disease in the presence of another is an important issue,[@b10-copd-10-1219],[@b11-copd-10-1219] but also there is a risk of over-diagnosing COPD in patients with HF if these patients are not stable and have some pulmonary congestion.[@b12-copd-10-1219] Pulmonary congestion is common in those hospitalized for an exacerbation of HF, and this may mimic COPD clinically, but also spirometrically. Spirometry at discharge in that situation would show -- caused by pulmonary congestion -- a larger reduction in forced expiratory volume in 1 second (FEV~1~) than in forced vital capacity (FVC), resulting in a risk of over-diagnosing COPD.[@b13-copd-10-1219],[@b14-copd-10-1219] When patients with HF are stable and euvolemic, the FEV~1~/FVC allows to adequately detect COPD, although, both the FEV~1~ and the FVC are reduced to a similar extent.[@b15-copd-10-1219] Diagnosing COPD at the right moment is therefore key in patients with HF.

Earlier reports on the prevalence of co-morbid COPD in HF often relied on previous documentation of COPD, or on spirometry results performed in HF patients when unstable.[@b10-copd-10-1219],[@b16-copd-10-1219],[@b17-copd-10-1219] Prevalence estimates ranged from 9% to 52%.[@b2-copd-10-1219] Data in a representative sample of patients with HF in a stable phase of their disease, also including patients with preserved ejection fraction (PEF), are still lacking.[@b1-copd-10-1219]

The aim of our study was to provide a valid prevalence estimate of COPD in a representative sample of patients with HF while in a stable condition (ClinicalTrials.gov identifier NCT01662323).

Methods
=======

Design and study population
---------------------------

In a cross-sectional study we enrolled patients from 30 general practices from the vicinity of Amersfoort, the Netherlands. The study and recruitment period was from November 2010 until October 2011. In total 70,000 persons were enlisted in these practices. In the Netherlands all citizens are registered with a general practitioner (GP), irrespective of cooperative care by a hospital specialist, including those living in a home for the elderly, but excluding those living in a nursing home or hospice. Patients were eligible if they had a diagnosis of HF confirmed by an expert panel consisting of two cardiologists and a GP specializing in HF using all diagnostic information, including echocardiography. The panel based the diagnosis of HF on the criteria of the European Society of Cardiology, that is, suggestive symptoms and objective evidence of cardiac structural or functional cardiac abnormality related to ventricular dysfunction at rest detectable with echocardiography. For HF with reduced ejection fraction (HF-REF) the left ventricular ejection fraction should be \<45%. For HF with preserved ejection fraction (HF-PEF) the left ventricular ejection fraction should be ≥45%, in addition to diastolic dysfunction identified by echocardiography.[@b18-copd-10-1219] Disagreement between panel members was resolved by majority. We invited 236 patients with a confirmed diagnosis of HF for spirometry, and 121 (51.2%) consented to participate ([Figure 1](#f1-copd-10-1219){ref-type="fig"}).

The study was approved by the Regional Medical Ethics Committee of the Meander Medical Center, Amersfoort, the Netherlands. All participants gave written informed consent.

Measurements
------------

Between November 2010 and June 2011 baseline characteristics of the participants were extracted from the medical files of the participating GPs. Participants underwent spirometry in the primary care setting performed by trained personnel. Spirometry was performed with SPIDA software (Spida 5) and microloop. Before and after 400 micrograms of salbutamol, the FVC and FEV~1~ were measured. COPD was considered present if the post-bronchodilator FEV~1~/FVC ratio was below 0.7, as defined by the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria.[@b5-copd-10-1219] Severity of pulmonary obstruction was expressed as the proportion of the predicted FEV~1~ (the latter based on "normal" values as derived from the population at large with the same age, sex, and height) and derived from the forced spirometry.[@b19-copd-10-1219] The FEV~1~ as percentage predicted was subdivided into four categories: ≥80, 50--79, 30--49, ≤30. The quality of the flow-volume curves was assessed by an experienced physician.

Data analysis
-------------

We compared HF patients who decided to participate with nonparticipants. In the participants we compared those with and without COPD. In those with COPD, we compared "already known" with "newly detected". Finally, we compared patients with HF-REF and HF-PEF. Differences between groups were assessed with the chi-square or Fisher's exact tests for categorical variables, and independent student's *t*-test for continuous variables. The prevalence of COPD was calculated with the binominal 95% confidence intervals (95% CIs). All data were analyzed with SPSS version 20.0.

Results
=======

Two-hundred and thirty-six patients with established HF were invited for spirometry. Baseline characteristics of the participants (n=121) were not significantly different from the nonparticipants (n=115) ([Table S1](#SD1-copd-10-1219){ref-type="supplementary-material"}). In 15 patients spirometry results were of insufficient quality, leaving 106 for this analysis ([Figure 1](#f1-copd-10-1219){ref-type="fig"}). The mean age of the 106 participants was 76.0 (standard deviation \[SD\] 11.9) years, and 57% were male. The prevalence of COPD was 28.3% (95% CI 19.7%--36.9%), with similar rates for those with a REF (28.6% \[95% CI 20.0%--37.2%\]) and PEF (27.9% \[95% CI 19.4%--36.4%\]).

[Table 1](#t1-copd-10-1219){ref-type="table"} shows patient characteristics of all 106 patients. On average, patients with COPD were older than those without COPD. Mean FEV~1~ % predicted was 65.8 (SD 19.5) and 73.9 (SD 10.9) for those with newly detected COPD and without COPD, respectively. Seventy percent of the subjects with COPD was previously undiagnosed by their GP. None of the patients with COPD had a history of asthma. [Table 2](#t2-copd-10-1219){ref-type="table"} shows the patient characteristics of newly detected cases vs HF patients without COPD. In [Table 3](#t3-copd-10-1219){ref-type="table"} we compared patients with HF-REF and HF-PEF. The mean post-dilator FEV~1~ % predicted was approximately 80% for both HF-REF and HF-PEF patients. Patients with HF-REF were more often male than those with HF-PEF.

Discussion
==========

In our study among stable community-dwelling HF patients the prevalence of COPD was 28.3%, and in 70% this was a new diagnosis of COPD. Prevalence rates were comparable for the subgroups of HF-REF and HF-PEF.

Our results are in line with previous studies reporting prevalence rates of 9%--52% in patients with HF.[@b2-copd-10-1219] These previous studies were performed in hospitalized patients with an over-representation of HF-REF, and spirometry was performed while these patients were recently pulmonary fluid overloaded. We could therefore provide a more valid point estimate of the COPD prevalence of the HF population at large than previous studies. A recent study among 118 elderly patients with stable HF and a smoking history of ≥10 pack years also showed a prevalence rate of 30% of COPD, similar to our study, and also a similarly high number of newly detected cases of COPD (64%).[@b20-copd-10-1219] In this study COPD was also defined according to the GOLD criteria. Moreover, patients were investigated while stable, approximately 3 months after being hospitalized for HF. Separate prevalence rates for HF-REF and HF-PEF, however, were lacking.[@b20-copd-10-1219]

The prevalence of COPD in patients with HF in our study is approximately 1.5 times higher than the expected estimate of 20% in elderly from the population at large.[@b21-copd-10-1219]

We found that the post-bronchodilator FEV~1~ in patients with HF was on average 80% of predicted in patients with the same age and length. This is in line with a previous study showing that HF in the absence of COPD may cause a reduction in FEV~1~ of approximately 20%, caused by HF itself.[@b15-copd-10-1219] Thus, classifying severity of COPD based on FEV~1~ % predicted may overestimate the severity of obstruction in patients with HF. Because both FVC and FVC as % predicted are reduced approximately 20%, the ratio FEV~1~/FVC is not affected.[@b15-copd-10-1219]

A strength of our study is the inclusion of a representative sample of patients with HF in a stable phase of their disease, and we could present prevalence rates for patients with HF-REF and HF-PEF separately.

A limitation is the relatively small sample size and the lack of body box measurements. Measurements of the total lung capacity and the residual volume would have been helpful to refine the diagnosis of COPD, especially in cases with spirometry results around the critical cut-off point of FEV~1~/FVC 0.7.[@b22-copd-10-1219] Importantly, however, previous studies reporting on the prevalence of COPD in HF did not apply pulmonary function tests other than spirometry. Recently, some authors advocated age- and sex-related thresholds for the FEV~1~/FVC lower limit of normal to define COPD.[@b19-copd-10-1219] We did not use one of the suggested lower limit of normal methods, because application in our study would reduce the possibility to compare our results with previous studies. Finally, some COPD cases may in fact represent persistent asthma, or "mixed cases", however, none of the COPD cases in earlier years had been labeled with asthma by the GP. We therefore preferred to use the GOLD-definition for COPD (a FEV~1~/FVC \<0.7). Knowledge of co-morbid COPD in patients with HF has clinical implications because for the management of breathlessness there is room for pulmonary inhalation drugs. We have, however, realized that some authors suggest that both beta-mimetics and anti-muscarinic agents may harm the heart. HF drugs may be prescribed in patients with COPD, including cardio selective β-blockers. It is, however, important to uptitrate slowly.[@b23-copd-10-1219]

Conclusion
==========

COPD is common in patients with HF, both HF-REF and HF-PEF, and remains undetected in the majority of patients. Selective screening of patients with HF when in a stable phase of their disease should be considered.

Supplementary material
======================

###### 

Characteristics of the 236 patients with established heart failure who were invited for spirometry, divided into participants and nonparticipants

                                Participants (n=121)   Nonparticipants (n=115)   *P*-value
  ----------------------------- ---------------------- ------------------------- -----------
  Male sex                      46.3                   55.7                      0.15
  Mean age in years (SD)        77.0 (11.4)            76.6 (11.9)               0.91
  Hypertension                  56.7                   53.0                      0.63
  Diabetes mellitus             30.6                   26.1                      0.44
  Prior myocardial infarction   33.1                   32.2                      0.89
  Angina pectoris               22.3                   13.0                      0.06
  Atrial fibrillation           54.5                   50.4                      0.53
  eGFR \<60 mL/m^2^             38.8                   37.4                      0.82
  Medication                                                                     
   Diuretics                    84.3                   73.0                      0.03
   ACE-i                        54.5                   52.2                      0.72
   β-blocker                    59.9                   52.2                      0.29
   Digoxin                      24.0                   21.7                      0.68

**Note:** Numbers are cases (%) unless specified otherwise.

**Abbreviations:** SD, standard deviation; eGFR, estimated glomerular filtration rate according to the modification of diet in renal diseases formula; ACE-i, angiotensin converting enzyme inhibitor.
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**Abbreviation:** HF, heart failure.](copd-10-1219Fig1){#f1-copd-10-1219}

###### 

Characteristics of the 106 patients with established heart failure divided into those with and without newly detected, or already known COPD

  Characteristics                                        Total         Newly detected COPD   Known COPD    No COPD
  ------------------------------------------------------ ------------- --------------------- ------------- -------------
  Mean age in years (SD)                                 76.0 (11.9)   76.9 (11.7)           76.4 (10.9)   75.8 (12.2)
  Male sex                                               60 (56.6)     14 (66.7)             9 (100.0)     37 (48.7)
  HF-REF                                                 63 (59.4)     12 (57.1)             6 (66.7)      45 (59.2)
  HF-PEF                                                 43 (40.6)     9 (42.9)              3 (33.3)      31 (40.8)
  Mean FVC as % predicted (SD)                           86.4 (21.0)   83.5 (16.8)           95.6 (14.5)   86.3 (24.0)
  Mean FEV~1~ as % predicted (SD)                        79.6 (22.1)   65.8 (19.5)           73.9 (10.9)   88.9 (22.8)
  Mean FEV~1~/FVC (SD)                                   74.5 (11.8)   60.2 (9.8)            58.0 (5.7)    78.3 (14.3)
  Smoking[\*](#tfn2-copd-10-1219){ref-type="table-fn"}                                                     
   Current                                               43 (47.3)     8 (47.1)              1 (14.3)      34 (50.8)
   Former                                                37 (40.7)     9 (52.9)              5 (71.4)      23 (34.3)
   Never                                                 11 (12.0)     0 (0.0)               1 (14.3)      10 (14.9)
  Co-morbidities                                                                                           
   Hypertension                                          55 (51.9)     12 (57.1)             4 (44.4)      39 (51.3)
   Diabetes mellitus                                     28 (26.4)     2 (9.5)               2 (22.2)      24 (31.6)
   Prior myocardial infarction                           35 (33.0)     9 (42.9)              4 (44.4)      22 (28.9)
  Cardiovascular medication                                                                                
   Diuretics                                             75 (70.8)     13 (61.9)             5 (55.6)      57 (75.0)
   ACE-i or ARB                                          67 (63.2)     15 (71.4)             4 (44.4)      49 (63.6)
   β-blockers                                            55 (51.9)     11 (52.4)             6 (66.7)      38 (50.0)
   Mineralocorticoid receptor antagonists                35 (33.0)     2 (9.5)               1 (11.1)      32 (42.1)
  Pulmonary medication:                                                                                    
   Inhaled beta-mimetics                                                                                   
    Short-acting                                         9 (8.4)       4 (19.0)              1 (11.1)      4 (5.3)
    Long-acting                                          13 (12.1)     3 (14.3)              4 (44.4)      6 (7.9)
   Inhaled anticholinergics                                                                                
    Short-acting                                         10 (9.3)      1 (4.8)               2 (22.2)      7 (9.2)
    Long-acting                                          3 (2.8)       0 (0.0)               3 (33.3)      0 (0.0)
   Corticosteroids                                                                                         
    Oral                                                 3 (2.8)       1 (4.8)               2 (22.2)      0 (0.0)
    Inhaled                                              14 (13.1)     4 (19.0)              4 (44.4)      6 (7.9)

**Notes:** Numbers are cases (%) unless mentioned otherwise.

Data on smoking were missing in 15 patients.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; SD, standard deviation; HF-REF, heart failure with reduced ejection fraction; HF-PEF, heart failure with preserved ejection fraction; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; ACE-i, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.

###### 

Characteristics of the patients with heart failure and a new diagnosis of COPD vs those without COPD

  Characteristics                          Newly diagnosed COPD (n=21)   No COPD (n=76)   *P*-value
  ---------------------------------------- ----------------------------- ---------------- -----------
  Mean age                                 76.9 (11.7)                   75.8 (12.2)      0.71
  Male sex                                 14 (66.7)                     37 (48.7)        0.14
  HF-REF                                   12 (57.1)                     45 (59.2)        0.87
  HF-PEF                                   9 (42.9)                      31 (40.8)        0.87
  Smoking                                                                                 
   Current                                 8 (47.1)                      34 (50.8)        0.59
   Former                                  9 (52.9)                      23 (34.3)        0.28
   Never                                   0 (0)                         10 (14.9)        0.79
  Cardiovascular medication                                                               
   Diuretics                               13 (61.9)                     57 (75.0)        0.24
   ACE-i or ARB                            15 (71.4)                     48 (63.2)        0.48
   β-blocker                               11 (52.4)                     38 (50.0)        0.85
   Mineralocorticoid receptor antagonist   2 (9.5)                       32 (42.1)        0.006

**Notes:** Numbers are cases (%) unless specified otherwise. Data on smoking were missing in 13 patients.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; HF-REF, heart failure with reduced ejection fraction; HF-PEF, heart failure with preserved ejection fraction; ACE-i, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.

###### 

Characteristics and spirometry results of the 106 patients with established HF, divided in those with HF-REF and HF-PEF

  Characteristics                           HF-REF (n=63)    HF-PEF (n=43)    *P*-value
  ----------------------------------------- ---------------- ---------------- -----------
  Mean age in years (SD)                    73.1 (13.0)      80.4 (8.4)       0.001
  Male sex                                  38 (60.3)        22 (51.2)        0.35
  Confirmed COPD                            18 (28.6)        12 (27.9)        0.94
  Spirometry results                                                          
   Mean FVC as % predicted                  85.9 (SD 22.9)   87.3 (SD 21.4)   0.77
   Mean FEV~1~ as % predicted               79.2 (SD 21.4)   80.3 (SD 23.7)   0.82
  FEV~1~ as % predicted                                                       
    ≥80                                     7 (11.1)         3 (7.0)          0.48
   50--79                                   9 (14.3)         7 (16.3)         0.78
   30--49                                   2 (3.2)          2 (4.7)          0.70
   \<30                                     0 (0)            0 (0)            1.0
  Cardiovascular medication                                                   
   Diuretics                                41 (65.1)        34 (79.1)        0.12
   ACE-i or ARB                             45 (71.4)        22 (51.2)        0.03
   β-blockers                               35 (55.6)        20 (46.5)        0.36
   Mineralocorticoid receptor antagonists   20 (31.7)        15 (34.9)        0.73

**Note:** Numbers are cases (%) unless specified otherwise.

**Abbreviations:** HF, heart failure; COPD, chronic obstructive pulmonary disease; SD, standard deviation; HF-REF, heart failure with reduced ejection fraction; HF-PEF, heart failure with preserved ejection fraction; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; ACE-i, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
